An open, single center two-step trial (A+B), comparing the safety and tolerability of idarubicin 10 mg and 15 mg after separate single hepatic intra-arterial injections of a drug formulation based on lipiodol emulsion in patients with unilobular or bilobular intermediate stage hepatocellular carcinoma.
Latest Information Update: 13 Sep 2021
At a glance
- Drugs Idarubicin (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics
- Acronyms TACTIDA
Most Recent Events
- 13 Sep 2021 New trial record